BIGH3 is a mediator of TGFβ-Induced collagen formation in fibrosis and pancreatic cancer and a potential therapeutic target.

ABSTRACT: Fibroblast-driven deposition of extracellular matrix, particularly type III collagen, is linked to poor outcomes in patients with liver fibrosis, fibrotic solid tumors such as hepatocellular carcinoma and pancreatic cancer as well as in patients with other fibrotic diseases. The pro-peptide of type III collagen (PRO-C3) serves as a serum biomarker of active collagen formation. PRO-C3 is elevated and prognostic in patients with liver fibrosis and pancreatic cancer, suggesting that targeting mechanisms behind PRO-C3 elevation could benefit these individuals. In this study, we sought to identify genetic variants associated with circulating PRO-C3 levels as potential therapeutic targets for fibrotic diseases and cancer. A genome-wide association study (GWAS) of the PERF cohort (n = 4968) ident

SUBMITTER: Willumsen N 

PROVIDER: S-EPMC12630801 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature